secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001104659-23-060978
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Q1 net loss narrows to $6.2M; cash runway into Q3 2023
------------------------------------------------------------

- Net loss of $6.2M ($2.88/sh) vs $11.6M ($5.36/sh) in Q1 2022; R&D and G&A expenses decreased.
- Cash and equivalents $4.9M at March 31; amended Hercules loan reduced minimum cash to $2.25M, interest-only until Sep 1, 2023.
- Current cash expected to fund operations into Q3 2023, assuming Phase 3 activities start in Q3.
- Topline data for ELX-02 in Alport syndrome (including biopsy) expected H1 2023; meaningful protein reduction seen in one patient.
- FDA cleared ZKN-013 SAD trial for RDEB; preclinical showed up to 18-fold increase in full-length COL VII protein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923060978/0001104659-23-060978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923060978/tm2315845d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer